Y.S.P. Southeast Asia Holding (7178) Fair Value & Analysis
Healthcare · MY · Market cap 289M MYR
Fair value as of: Jul 18, 2026
From 25 valuation models · updated 23 days ago
Share price +1.0% over the past month.
A solid business, screening 90% undervalued on our models.
What matters now
- The rarer combination: high quality (72/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (2.91 MYR). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range 1.62 MYR – 2.71 MYR · fair‑value band 2.91 MYR – 4.85 MYR · the 2.04 MYR price screens below the 3.88 MYR fair value. Dashed = 300-day average. As of Jul 18, 2026.
Analysis
Y.S.P. Southeast Asia Holding (7178) currently trades at 2.04 MYR, while our model-based Fair Value estimate is 3.88 MYR, implying the stock looks roughly 90.2% undervalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Y.S.P. Southeast Asia Holding generated revenue of 363M MYR at a net margin of 6.5%. Revenue declined 1.9% year over year. It earns a return on equity of 5.5%. The stock trades on a trailing P/E of 12.2. Fundamentals as of Jul 18, 2026
Our scenario range runs from 2.91 MYR (bear case) to 4.85 MYR (bull case); at 2.04 MYR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 7% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 90%, 7178 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: DCF Models (4.52 MYR) versus Dividend Discount (1.45 MYR). Highest evidence: Growth DCF (80).
Notify me when 7178 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 72 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, engages in the manufacturing and trading of generic drugs in Malaysia, Singapore, Vietnam, Philippines, Cambodia, Myanmar, Brunei, Indonesia, Thailand, Africa, and internationally. It operates through three segments: Manufacturing, Trading, and Investment Holding.
Full company description
Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, engages in the manufacturing and trading of generic drugs in Malaysia, Singapore, Vietnam, Philippines, Cambodia, Myanmar, Brunei, Indonesia, Thailand, Africa, and internationally. It operates through three segments: Manufacturing, Trading, and Investment Holding. The company manufactures, sells, imports, exports, trades in, and distributes pharmaceutical and veterinary products, pharmaceutical fine chemicals, raw material, health food products, and medical devices. It also manufactures aquatic, cosmetic, and biotechnology and health products, as well as traditional herbal medicines, food and health supplements, and over-the-counter products; and offers management services. Y.S.P. Southeast Asia Holding Berhad was founded in 1987 and is headquartered in Kuala Lumpur, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Y.S.P. Southeast Asia Holding reported revenue of 365M MYR in FY2025 versus 282M MYR in FY2021, a compound +6.7%/yr. Reported net income was 25.0M MYR in FY2025, compounding +13.3%/yr from FY2021.
Watch 7178: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Y.S.P. Southeast Asia Holding with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Y.S.P. Southeast Asia Holding (7178) overvalued or undervalued?
What is the fair value of 7178?
What is the quality score of 7178?
What is the revenue of Y.S.P. Southeast Asia Holding (7178)?
What is the net profit margin of 7178?
Does Y.S.P. Southeast Asia Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Y.S.P. Southeast Asia Holding and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.